Which has stronger earnings & valuation, TFX or NVCR?

NovoCure has lower revenue, but higher earnings than Teleflex. NovoCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teleflex $1.99B 3.04 -$905.64M -$23.29 N/A NovoCure $655.35M 3.00 -$136.23M -$1.30 N/A

Is TFX or NVCR more profitable?

NovoCure has a net margin of -21.25% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Teleflex -39.67% 11.93% 5.44% NovoCure -21.25% -44.00% -15.85%

Does the media refer more to TFX or NVCR?

In the previous week, Teleflex had 28 more articles in the media than NovoCure. MarketBeat recorded 30 mentions for Teleflex and 2 mentions for NovoCure. NovoCure's average media sentiment score of 0.76 beat Teleflex's score of 0.56 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teleflex 8 Very Positive mention(s) 5 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MMED or NVCR?

In the previous week, NovoCure had 1 more articles in the media than MiniMed Group. MarketBeat recorded 2 mentions for NovoCure and 1 mentions for MiniMed Group. NovoCure's average media sentiment score of 0.76 beat MiniMed Group's score of 0.67 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, LIVN or NVCR?

NovoCure has lower revenue, but higher earnings than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.05 -$242.47M $3.38 22.76 NovoCure $655.35M 3.00 -$136.23M -$1.30 N/A

Is LIVN or NVCR more profitable?

LivaNova has a net margin of 12.82% compared to NovoCure's net margin of -21.25%. LivaNova's return on equity of 16.35% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% NovoCure -21.25% -44.00% -15.85%

Does the media refer more to LIVN or NVCR?

In the previous week, LivaNova had 13 more articles in the media than NovoCure. MarketBeat recorded 15 mentions for LivaNova and 2 mentions for NovoCure. NovoCure's average media sentiment score of 0.76 beat LivaNova's score of 0.76 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 5 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, NVCR or ITGR?

Integer has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 3.00 -$136.23M -$1.30 N/A Integer $1.85B 2.30 $102.81M $3.66 34.23

Is NVCR or ITGR more profitable?

Integer has a net margin of 6.97% compared to NovoCure's net margin of -21.25%. Integer's return on equity of 12.79% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -21.25% -44.00% -15.85% Integer 6.97% 12.79% 6.48%

Does the media prefer NVCR or ITGR?

In the previous week, Integer had 20 more articles in the media than NovoCure. MarketBeat recorded 22 mentions for Integer and 2 mentions for NovoCure. NovoCure's average media sentiment score of 0.76 beat Integer's score of 0.74 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Integer 11 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, HAE or NVCR?

Haemonetics has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.35B 2.94 $97.31M $2.04 42.93 NovoCure $655.35M 3.00 -$136.23M -$1.30 N/A

Is HAE or NVCR more profitable?

Haemonetics has a net margin of 7.12% compared to NovoCure's net margin of -21.25%. Haemonetics' return on equity of 27.55% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.12% 27.55% 9.65% NovoCure -21.25% -44.00% -15.85%

Does the media favor HAE or NVCR?

In the previous week, Haemonetics had 28 more articles in the media than NovoCure. MarketBeat recorded 30 mentions for Haemonetics and 2 mentions for NovoCure. NovoCure's average media sentiment score of 0.76 beat Haemonetics' score of 0.62 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 6 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NovoCure (NVCR) Competitors

$16.86 +0.47 (+2.86%)

As of 09:46 AM Eastern

Compare

NVCR vs. TFX, MMED, LIVN, ITGR, and HAE

Should you buy NovoCure stock or one of its competitors? MarketBeat compares NovoCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NovoCure include Teleflex (TFX), MiniMed Group (MMED), LivaNova (LIVN), Integer (ITGR), and Haemonetics (HAE). These companies are all part of the "healthcare equipment" industry.

How does NovoCure compare to Teleflex?

Teleflex (NYSE:TFX) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

NovoCure has lower revenue, but higher earnings than Teleflex. NovoCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$1.99B	3.04	-$905.64M	-$23.29	N/A
NovoCure	$655.35M	3.00	-$136.23M	-$1.30	N/A

95.6% of Teleflex shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 0.7% of Teleflex shares are owned by company insiders. Comparatively, 6.6% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

NovoCure has a net margin of -21.25% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
NovoCure	-21.25%	-44.00%	-15.85%

Teleflex presently has a consensus price target of $149.80, suggesting a potential upside of 9.60%. NovoCure has a consensus price target of $21.20, suggesting a potential upside of 25.75%. Given NovoCure's higher possible upside, analysts plainly believe NovoCure is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Teleflex had 28 more articles in the media than NovoCure. MarketBeat recorded 30 mentions for Teleflex and 2 mentions for NovoCure. NovoCure's average media sentiment score of 0.76 beat Teleflex's score of 0.56 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teleflex	8 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teleflex has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Summary

Teleflex beats NovoCure on 10 of the 17 factors compared between the two stocks.

How does NovoCure compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

NovoCure has lower revenue, but higher earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.10B	1.80	-$333M	-$0.68	N/A
NovoCure	$655.35M	3.00	-$136.23M	-$1.30	N/A

MiniMed Group currently has a consensus price target of $21.62, indicating a potential upside of 8.65%. NovoCure has a consensus price target of $21.20, indicating a potential upside of 25.75%. Given NovoCure's higher probable upside, analysts clearly believe NovoCure is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, NovoCure had 1 more articles in the media than MiniMed Group. MarketBeat recorded 2 mentions for NovoCure and 1 mentions for MiniMed Group. NovoCure's average media sentiment score of 0.76 beat MiniMed Group's score of 0.67 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiniMed Group has a net margin of 0.00% compared to NovoCure's net margin of -21.25%. MiniMed Group's return on equity of 0.00% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
NovoCure	-21.25%	-44.00%	-15.85%

84.6% of NovoCure shares are held by institutional investors. 6.6% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

NovoCure beats MiniMed Group on 8 of the 15 factors compared between the two stocks.

How does NovoCure compare to LivaNova?

LivaNova (NASDAQ:LIVN) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

LivaNova presently has a consensus target price of $83.50, suggesting a potential upside of 8.55%. NovoCure has a consensus target price of $21.20, suggesting a potential upside of 25.75%. Given NovoCure's higher possible upside, analysts plainly believe NovoCure is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

LivaNova has a net margin of 12.82% compared to NovoCure's net margin of -21.25%. LivaNova's return on equity of 16.35% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
NovoCure	-21.25%	-44.00%	-15.85%

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 6.6% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

NovoCure has lower revenue, but higher earnings than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.05	-$242.47M	$3.38	22.76
NovoCure	$655.35M	3.00	-$136.23M	-$1.30	N/A

In the previous week, LivaNova had 13 more articles in the media than NovoCure. MarketBeat recorded 15 mentions for LivaNova and 2 mentions for NovoCure. NovoCure's average media sentiment score of 0.76 beat LivaNova's score of 0.76 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	5 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LivaNova beats NovoCure on 12 of the 17 factors compared between the two stocks.

How does NovoCure compare to Integer?

NovoCure (NASDAQ:NVCR) and Integer (NYSE:ITGR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Integer has a net margin of 6.97% compared to NovoCure's net margin of -21.25%. Integer's return on equity of 12.79% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-21.25%	-44.00%	-15.85%
Integer	6.97%	12.79%	6.48%

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 6.6% of NovoCure shares are owned by insiders. Comparatively, 1.1% of Integer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NovoCure currently has a consensus price target of $21.20, suggesting a potential upside of 25.75%. Integer has a consensus price target of $109.86, suggesting a potential downside of 12.31%. Given NovoCure's stronger consensus rating and higher probable upside, analysts plainly believe NovoCure is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

In the previous week, Integer had 20 more articles in the media than NovoCure. MarketBeat recorded 22 mentions for Integer and 2 mentions for NovoCure. NovoCure's average media sentiment score of 0.76 beat Integer's score of 0.74 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Integer	11 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Integer has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.00	-$136.23M	-$1.30	N/A
Integer	$1.85B	2.30	$102.81M	$3.66	34.23

NovoCure has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Integer has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Summary

Integer beats NovoCure on 9 of the 16 factors compared between the two stocks.

How does NovoCure compare to Haemonetics?

Haemonetics (NYSE:HAE) and NovoCure (NASDAQ:NVCR) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Haemonetics has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.35B	2.94	$97.31M	$2.04	42.93
NovoCure	$655.35M	3.00	-$136.23M	-$1.30	N/A

Haemonetics has a net margin of 7.12% compared to NovoCure's net margin of -21.25%. Haemonetics' return on equity of 27.55% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
NovoCure	-21.25%	-44.00%	-15.85%

Haemonetics presently has a consensus target price of $90.89, suggesting a potential upside of 3.79%. NovoCure has a consensus target price of $21.20, suggesting a potential upside of 25.75%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 2.1% of Haemonetics shares are owned by company insiders. Comparatively, 6.6% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Haemonetics had 28 more articles in the media than NovoCure. MarketBeat recorded 30 mentions for Haemonetics and 2 mentions for NovoCure. NovoCure's average media sentiment score of 0.76 beat Haemonetics' score of 0.62 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	6 Very Positive mention(s)	4 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Haemonetics has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Summary

Haemonetics beats NovoCure on 12 of the 17 factors compared between the two stocks.

Get NovoCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCR vs. The Competition

Export

Metric	NovoCure	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.91B	$5.76B	$7.00B	$12.99B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	-12.97	24.25	270.57	25.05
Price / Sales	3.00	68.34	659.56	107.93
Price / Cash	N/A	33.55	28.89	37.44
Price / Book	5.55	6.11	11.20	6.43
Net Income	-$136.23M	$149.01M	$3.45B	$348.10M
7 Day Performance	10.05%	2.35%	3.39%	2.66%
1 Month Performance	3.43%	0.62%	-0.72%	-0.85%
1 Year Performance	51.47%	4.91%	77.42%	23.96%

NovoCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCR NovoCure	3.2432 of 5 stars	$16.86 +2.9%	$21.20 +25.7%	+47.3%	$1.91B	$655.35M	N/A	1,605	Analyst Upgrade Gap Down
TFX Teleflex	3.7608 of 5 stars	$139.86 +2.3%	$148.90 +6.5%	+13.4%	$6.05B	$1.99B	N/A	15,500	Earnings Report Dividend Announcement Analyst Forecast High Trading Volume
MMED MiniMed Group	2.3366 of 5 stars	$19.10 +5.8%	$21.62 +13.2%	N/A	$5.36B	$3.10B	N/A	8,000
LIVN LivaNova	3.1512 of 5 stars	$82.46 +2.9%	$81.38 -1.3%	+56.1%	$4.40B	$1.39B	42.29	3,300	Positive News Earnings Report
ITGR Integer	2.4128 of 5 stars	$124.45 +2.7%	$103.71 -16.7%	+17.5%	$4.12B	$1.85B	31.03	11,000	Earnings Report High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NovoCure (NVCR) Competitors